Cellectis (CLLS) Cash from Operations Growth (1y) (2016 - 2026)
Cellectis (CLLS) Cash from Operations Growth (1y) (2016 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,981.90 Bn | 66,981.62 Bn | - | 7.14% |
| 2 | Nanobiotix | 1,930.48 Bn | 1,930.42 Bn | - | - |
| 3 | Akari Therapeutics | 1,071.19 Bn | 1,071.19 Bn | - | - |
| 4 | BeOne Medicines | 468.55 Bn | 463.76 Bn | 1.35 Bn | 356.73% |
| 5 | Vertex Pharmaceuticals | 123.04 Bn | 115.79 Bn | 2.59 Bn | 74.39% |
| 6 | Regeneron Pharmaceuticals | 70.31 Bn | 61.56 Bn | 3.31 Bn | 3.23% |
| 7 | Belite Bio | 63.40 Bn | 63.40 Bn | - | - |
| 8 | Argenx Se | 55.78 Bn | 50.60 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.67 Bn | 34.66 Bn | 959.66 Mn | 158.60% |
| 10 | Cellectis | 286.65 Mn | 100.99 Mn | - | 10.20% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 10.20% |
| Dec 31, 2025 | -21,942.55% |
| Sep 30, 2025 | 73.05% |
| Jun 30, 2025 | -119.76% |
| Mar 31, 2025 | 26.40% |
| Dec 31, 2024 | -100.13% |
| Sep 30, 2024 | 65.90% |
| Jun 30, 2024 | 400.35% |
| Mar 31, 2024 | 11.52% |
| Dec 31, 2023 | 1,501.82% |
| Sep 30, 2023 | 25.30% |
| Jun 30, 2023 | 5.84% |
| Mar 31, 2023 | 11.45% |
| Dec 31, 2022 | 110.68% |
| Sep 30, 2022 | 24.79% |
| Jun 30, 2022 | -52.17% |
| Mar 31, 2022 | 27.29% |
| Dec 31, 2021 | -399.76% |
| Sep 30, 2021 | -18.81% |
| Jun 30, 2021 | 45.44% |